U.S. Ophthalmic Compounding Pharmacies Market

研究執行與發布：Coherent Market Insights　·　發布日期 2026-03-06　·　152 頁
由量子訊息有限公司（Quantum Information）在台灣代理銷售與提供授權諮詢。

2026 年市場規模: USD 4.3 Bn
2033 年預估規模: USD 6.6 Bn
年複合成長率 CAGR: 5.2%

以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。

出版商 Coherent Market Insights 產業別 Healthcare & Life Sciences出版日期 2026-03-06頁數 152報告編號 CMI4921

授權報價

Single User Price	$4,500 USD
Enterprise License	$10,000 USD

洽詢購買申請 Sample

完整報告名稱與涵蓋範圍

U.S. Ophthalmic Compounding Pharmacies Market, By Drug (Mitomycin, Amphotericin, Fluconazole, Voriconazole, Tropicamide, Atropine Sulfate, Albumin 5%, Cyclosporine 0.5-2%, Moxifloxacin, Gentamicin, Vancomycin, Amikacin, Tobramycin, Tetracycline, Metronidazole, Acetylcysteine, Bevacizumab, Tacrolimus, Retinoic Acid, Carosine, Latanoprost, Dorzolamide, Brimonidine, Timolol, and Others), By Formulation (Eye Drops, Ointments, Injections, and Others), By Therapeutic Application (Dry Eyes, Glaucoma, Cataracts, Conjunctivitis, Age-related Macular Degeneration, Uveitis (Eye Inflammation), and Others), By Pharmacy Type (503A and 503B)

報告摘要

When a commercially available medicine does not fit the unique needs of an individual patient (human or animal), the drug is compounded by a certified pharmacist. When a patient may be unable to tolerate a commercially available drug, or when the particular formulation required may be unavailable, or the patient may require a treatment that is currently in short supply or has been withdrawn, compounding is carried out. Compounding is defined by the United States Pharmacopeia Convention (USP) as the preparation, mixing, assembling, altering, packaging, and labelling of a drug, drug-delivery device, or device under a licensed practitioner's prescription, medication order, or initiative in the course of professional practice. Market Dynamics The increasing launches of drugs and adoption of inorganic strategies such as collaborations by the key players operating in the market are expected to drive the market growth during the forecast period. For instance, in November 2020, Fagron Sterile Services, a U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA)-registered 503B outsourcing provider of sterile medications, launched its new innovative silicone-free bevacizumab (AVASTIN) injection using Groninger automation technology in collaboration with West Pharmaceutical Services, Inc., a U.S.-based pharmaceutical company. This silicon-free AVASTIN injection has a long shelf life of 150 days and can be administered safely for ophthalmic applications without depositing any unsafe silicon oil droplets into the eye. Key features of the study • This report provides an in-depth analysis of the U.S. ophthalmic compounding pharmacies market and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players • It profiles key players in the U.S. ophthalmic compounding pharmacies market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies • Key companies covered as a part of this study include Fagron Sterile Services US, New Drug Loft & VLS Pharmacy, Nora Apothecary, Lifecare Pharmacy, Avella Specialty Pharmacy, Triangle Compounding Pharmacy, O’Brien Pharmacy, Tache Pharmacy, Northmark Pharmacy, Edge Pharma, and ImprimisRx • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics • The U.S. ophthalmic compounding pharmacies market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. ophthalmic compounding pharmacies market Market Segmentation • By Drug o Mitomycin o Amphotericin o Fluconazole o Voriconazole o Tropicamide o Atropine Sulfate o Albumin 5% o Cyclosporine 0.5-2% o Moxifloxacin o Gentamicin o Vancomycin o Amikacin o Tobramycin o Tetracycline o Metronidazole o Acetylcysteine o Bevacizumab o Tacrolimus o Retinoic Acid o Carosine o Latanoprost o Dorzolamide o Brimonidine o Timolol o Others • By Formulation o Eye Drops o Ointments o Injections o Others • By Therapeutic Application o Dry Eyes o Glaucoma o Cataracts o Conjunctivitis o Age-related Macular Degeneration o Uveitis (Eye Inflammation) o Others • By Pharmacy Type o 503A o 503B • Key Players Insights o Fagron Sterile Services US o New Drug Loft & VLS Pharmacy o Nora Apothecary o Lifecare Pharmacy o Avella Specialty Pharmacy o Triangle Compounding Pharmacy o O’Brien Pharmacy o Tache Pharmacy o Northmark Pharmacy o Edge Pharma o ImprimisRx.

目錄 Table of Contents

Table of Contents 1. Research Objectives and Assumptions o Research Objectives o Assumptions o Abbreviations 2. Market Purview o Report Description  Market Definition and Scope o Executive Summary  Market Snapshot, By Drug  Market Snapshot, By Formulation  Market Snapshot, By Therapeutic Application  Market Snapshot, By Pharmacy Type o Coherent Opportunity Map (COM) 3. Market Dynamics, Regulations, and Trends Analysis o Market Dynamics  Drivers  Restraints  Market Opportunities o Impact Analysis o Epidemiology o PEST Analysis o Mergers And Acquisition Scenario o Reimbursement Scenario o Regulatory Scenario o Outsourcing Facility Checklist o Distribution Channel o Compounding Drug Overview o List Of Registered Outsourcing Facilities o Pricing Analysis o Compounding Drugs Insights 4. U.S. Ophthalmic Compounding Pharmacies Market, By Drug, 2026 – 2033, (USD Bn) o Overview  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021-2033  Segment Trends o Mitomycin  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Amphotericin  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Fluconazole  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Voriconazole  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Tropicamide  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Atropine Sulfate  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Albumin 5%  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Cyclosporine 0.5-2%  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Moxifloxacin  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Gentamicin  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Vancomycin  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Amikacin  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Tobramycin  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Tetracycline  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Metronidazole  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Acetylcysteine  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Bevacizumab  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Tacrolimus  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Retinoic Acid  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Carosine  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Latanoprost  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Dorzolamide  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Brimonidine  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Timolol  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Others  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 5. U.S. Ophthalmic Compounding Pharmacies Market, By Formulation, 2026 – 2033, (USD Bn) o Overview  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021-2033  Segment Trends o Eye Drops  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Ointments  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Injections  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Others  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 6. U.S. Ophthalmic Compounding Pharmacies Market, By Therapeutic Application, 2026 – 2033, (USD Bn) o Overview  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021-2033  Segment Trends o Dry Eyes  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Glaucoma  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Cataracts  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Conjunctivitis  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Age-related Macular Degeneration  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Uveitis (Eye Inflammation)  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Others  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 7. U.S. Ophthalmic Compounding Pharmacies Market, By Pharmacy Type, 2026 – 2033, (USD Bn) o Overview  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021-2033  Segment Trends o 503A  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o 503B  Overview  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 8. Competitive Landscape o Fagron Sterile Services US  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o New Drug Loft & VLS Pharmacy  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Nora Apothecary  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Lifecare Pharmacy  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Avella Specialty Pharmacy  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Triangle Compounding Pharmacy  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o O’Brien Pharmacy  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Tache Pharmacy  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Northmark Pharmacy  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Edge Pharma  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o ImprimisRx  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies 9. Section o Research Methodology o About Us

提及公司

Fagron Sterile Services USNew Drug Loft & VLS PharmacyNora ApothecaryLifecare PharmacyAvella Specialty PharmacyTriangle Compounding PharmacyO’Brien PharmacyTache PharmacyNorthmark PharmacyEdge PharmaImprimisRx.

同分類最新報告（醫療與生命科學）

常見問題

這份報告可以先索取樣本嗎？

可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算？

報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付？如何付款？

一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・聯絡我們